ArticleActa neuropathologica1986
Cytoskeletal properties and endogenous degradation of glial fibrillary acidic protein and vimentin in cultured human glioma cells.
Article in Acta neuropathologica, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 22 citations in OpenAlex.
- Spinal cord-notochord relationship in normal human embryos and in a human embryo with double spinal cord.Acta neuropathologica · 1993Article
- Glial fibrillary acidic protein, vimentin and fibronectin in primary cultures of human glioma and fetal brain.Acta neuropathologica · 1988Article
- Products of cells cultured from gliomas. VI. Immunofluorescent, morphometric, and ultrastructural characterization of two different cell types growing from explants of human gliomas.The American journal of pathology · 1987Article
- Glial filaments in the subcutaneous tumors of mouse glioma clones differently expressing glial fibrillary acidic protein. An immunohistochemical and ultrastructural study.Acta neuropathologica · 1987Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cytoskeletal properties and endogenous degradation of intermediate filaments in cultured human glioma cells (U-251MG) were studied using monoclonal antibodies in immunohistochemical and immunochemical methods. Both glial fibrillary acidic protein (GFAP)- and vimentin-antibodies gave a fibrillar cytoplasmic staining of the cells, and double immunofluorescence experiments showed the presence of both types of intermediate filaments in the same cells. GFAP and vimentin could also be located to typical coiling perinuclear bundles after vinblastine treatment of the cultures. In the detergent-resistant, adherent cytoskeletons of the glioma cells, both GFAP and vimentin persisted as fibrillar cytoplasmic arrays. Scanning and transmission electron microscopy showed that only intermediate filaments were left in the cytoplasmic domain. Electrophoretic analysis, combined with the immunoblotting method, revealed that the two major detergent-resistant cytoskeletal polypeptides of the cells, with molecular weights of 51 kD and 58 kD, were GFAP and vimentin, respectively. On the other hand, neither GFAP nor vimentin were detected in the detergent extracts of the glioma cells. Detergent-extraction in low ionic strength medium as well as inclusion of Ca2+ into the extraction medium resulted into a rapid degradation of both GFAP and vimentin. These degradation conditions produced different, partially soluble, lower MW immunoreactive polypeptides as detected by the immunoblotting technique. Interestingly, the degradation also produced soluble intact GFAP and vimentin. These results indicate that GFAP and vimentin have closely similar physicochemical properties in the cytoskeletons of human glioma cells including a nearly quantitative localization in filaments, rearrangement upon microtubule disruption, and resistance to extractions by detergents. Proteolytic degradation of both proteins can be induced by a protease activated by both low ionic strength and Ca2+.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.